Skip to main content
. Author manuscript; available in PMC: 2017 Aug 15.
Published in final edited form as: Cancer Res. 2016 Jun 20;76(16):4805–4815. doi: 10.1158/0008-5472.CAN-15-2323

Figure 5. Cmpd-43 exhibits anti-cancer activity towards melanoma cell line MeWo.

Figure 5

A and B. Differential expression of PRL1 (A) or PRL2 (B) mRNA between normal skin samples (n=141) and melanoma patient samples (n=302). C. Kaplan-Meier survival analysis of 110 melanoma patients, grouped by their status of PRL1 mRNA expression level. D. Cmpd-43 does-dependently suppressed MeWo cell proliferation. E. Cmpd-43 significantly reduced MeWo cell motility. Total distance is the average of full track length of more than 600 cells over 6 h. F. Cmpd-43 dose-dependently inhibited the HGF-induced ERK1/2 and Akt activation in MeWo cells. G. Cmpd-43 (2.5 μM) suppressed PRL1-overexpression induced ERK1/2 and Akt activation. H. The inhibitory effect of Cmpd-43 towards HGF-induced ERK1/2 and Akt activation was significantly compromised in MeWo cells treated with siRNAs for both PRL1 and PRL2. I. The quantification of ERK1/2 and Akt activation in MeWo cells treated with either scramble siRNA or siRNAs for both PRL1 and PRL2. *p<0.05 (Student's t test) compared with DMSO control group. Data are representative of three independent experiments (mean and SD).